The short version.

• India’s pharma exports hit $31.1 billion in 2025-26, up 2.1 per cent — the industry’s own $32 billion target was missed.
• Three-quarters of that book is one line: retail-pack medicaments, which grew a bare 0.7 per cent and is the entire FY26 story.
• A US Section 232 tariff hit patented drugs at 100 per cent from April 2026 — but exempted generics, which is nearly everything India sells. The exemption comes up for review within a year.
• Meanwhile 43.45 per cent of India’s pharma imports come from China, and China supplies 70 per cent or more of 97 distinct active ingredients.
• The flagship scheme built to fix that — the Bulk Drugs PLI — has produced ₹2,720 crore of cumulative sales against a ₹6,940 crore outlay. The Pharmaceuticals PLI, aimed at scale rather than import substitution, produced 116 times more.

A good year that missed its own number

India’s pharmaceutical exports reached $31.1 billion in FY2025-26, per Pharmexcil, up 2.1 per cent on the year and worth ₹2,75,078 crore. Growth resumed at pace in the first quarter of FY2026-27. Read as a headline, it is a good year. Read by category, it is one line doing all the work.

Pharmexcil FY2025-26. The published category split does not sum to 100 per cent; the gap is shown as a residual rather than rebased, which is the more honest choice and the one this article follows throughout.

Where it goes, and what just changed there

Destinations are the more interesting cut, because the largest one just took a policy hit.

Pharmexcil, FY2025-26. Rest of world is a derived residual so shares sum to exactly 100 per cent.

The US share fell from 34.5 per cent in FY2024-25 to 30.44 per cent in FY2025-26, and the FY25 figure was itself inflated by roughly a $1.6 billion pre-buy ahead of feared tariffs — buyers stocking up before a threat that then arrived. March 2026 exports to the US fell 23 per cent in a single month; the rest of the year, April to February, ran 5.6 per cent ahead. One month carries the entire FY26 shortfall.

That table hides a second fact: the US concentration is not spread evenly across what India sells, it sits almost entirely in one product category. Pulling India’s FY2025-26 country-wise trade for four large HS-30 lines shows two very different destination shapes sitting inside the same $31 billion figure.

This article’s own analysis of DGCI&S/TradeStat country-wise export data for FY2025-26, pulled at HS-8 digit level. HHI on destination shares; above roughly 1,500 is generally read as concentrated. Not a Pharmexcil series and not directly comparable to the category totals above it, which come from Pharmexcil’s own classification.

Packaged medicaments — the largest of the four, and the closest single line to “India’s generic export business” — sends 41 per cent of its value to one country and 48 per cent to three. That is the line the Section 232 conversation is really about, because it is the one line where a US policy shift can move the whole number. Vaccines look nothing like it: the top destination is Nigeria at 16 per cent, followed by DR Congo, Pakistan, Indonesia and Bangladesh, and the top three markets together hold barely more than a third of the total. A public-health-procurement export book and a commercial-generics export book are travelling to different parts of the world, at different levels of customer concentration, inside the same export figure. The tariff risk table above is really a statement about one HS line, not about Indian pharma exports in general.

The tariff that missed India’s book almost entirely

On 2 April 2026 the United States issued a Section 232 proclamation imposing a 100 per cent tariff on patented pharmaceuticals, effective 31 July 2026 for most importers and 29 September 2026 for seventeen named large drug companies. Japan, the EU, South Korea, Switzerland and Liechtenstein were carved out at 15 per cent instead.

India was not carved out. India was exempted on a different basis entirely: the proclamation excludes generics and biosimilars from the tariff altogether, and India’s export book is overwhelmingly generic. The exemption is not a country concession. It is a category one, and it happens to cover almost everything India sells.

That protection is explicitly temporary. The proclamation sets an announced schedule — 0 per cent until 1 August 2028, then 100 per cent, then 200 per cent from 2029 — and directs the US Commerce Department to review the generics exclusion within one year. Nothing is enforced yet. The real decision point is 2027-28, and it sits over roughly $9.5 billion of annual exposure, essentially the entire US line in the table above.

The dependence the tariff conversation skips

Exports are one branch. Imports are a separate, never-netted branch, and this is where the industry’s exposure actually sits.

Department of Pharmaceuticals / DGCI&S series. Never netted against the Pharmexcil export figures above — the two series are differently based.

Set the two branches side by side and the shape of the industry is legible. India exports finished formulations at scale to the United States and beyond. The chemistry that goes into those formulations — the active pharmaceutical ingredients and their intermediates — disproportionately arrives from China first. India is a formulation superpower built on an intermediate-goods dependency, and the two facts sit inside the same trade account without ever appearing on the same line.

The scheme built to fix it, and the one that actually scaled

Two production-linked incentive schemes ran over the same period with the same acronym and opposite outcomes.

To December 2025 (Bulk Drugs) and September 2025 (Pharmaceuticals). The Bulk Drugs scheme approved 48 projects, commissioned 38, added about 56,800 tonnes of capacity and localised 28 molecules including Penicillin G, Clavulanic Acid, Rifampicin and Atorvastatin. The Pharmaceuticals PLI contributed 30 per cent of bulk drug exports and 26.5 per cent of formulation exports in FY2024-25.

That is not a failure of execution so much as a mismatch of scale. Import substitution in fermentation-based bulk chemistry is capital-intensive, slow to commission and competes against Chinese producers who have run at scale for two decades. Twenty-eight molecules localised in five years, including three of the harder ones on India’s own dependency list, is real progress. It is also nowhere near enough to move the 43.45 per cent number.

The BIOSECURE opportunity, and why it does not resolve the contradiction

A parallel American policy points the other way. The BIOSECURE Act, enacted December 2025 as part of the FY2026 defence authorisation, restricts US government contracting with named Chinese biotech firms — the trigger was WuXi AppTec’s placement on a Department of Defense list. Contracting restrictions bite in late 2027 to 2028.

Analysts size the opportunity for Indian contract research and manufacturing at roughly $700 million a year, or $2.4 billion over four years, against a sector already running $3.0–3.5 billion in FY26 sales and growing at an 18 per cent CAGR to FY2030. Named beneficiaries include Divi’s, Laurus and Sai Life. No concrete FY26 contract wins were found in the sources compiled for this piece — the opportunity currently lives in analyst sizing and share prices, not in booked revenue.

The contradiction is structural rather than tactical. India’s pitch to American biotech buyers is implicitly “China-free.” India cannot make that claim credibly while sourcing 43 per cent of its own pharma imports, and at least 70 per cent of 97 individual active ingredients, from China. A buyer who cares enough about China exposure to trigger BIOSECURE contracting rules is exactly the buyer who will ask where the intermediate chemistry comes from.

Whose numbers to trust, and when they disagree

Two commercial panels track the Indian domestic pharmaceutical market, IQVIA and PharmaTrac/AWACS, and they do not agree. IQVIA puts FY26 market growth at 10.0 per cent (volume +2.7, price +4.4, new products +2.8); PharmaTrac puts the market at ₹2,45,943 crore, up 8.6 per cent in value and just 0.6 per cent in units. That is a 1.4-point gap on growth and a 2.1-point gap on volume, from two houses measuring the same market.

The gap matters at company level. Macleods ranks 9th on IQVIA and 11th on PharmaTrac — the widest disagreement in the top twenty. Mankind reports 14.4 per cent India growth against 5.6 per cent on PharmaTrac’s secondary-sales measure, the largest primary-versus-secondary gap in the table; a company can genuinely be shipping more into the channel than pharmacies are selling out of it, and the two panels are measuring different points in that pipe. Neither panel is wrong. They are measuring different things, and any single-source claim about “the” Indian pharma market growth rate is quietly picking one of two disagreeing answers.

Cross-checking the headline number against trade data

Pharmexcil’s $31.1 billion figure is an industry-body number, not a customs one, and it is worth checking against the primary trade classification. DGCI&S records $25.1 billion of FY2025-26 exports under HS Chapter 30, pharmaceutical products — formulations, vaccines, immunological products. That alone is short of Pharmexcil’s figure by roughly six billion dollars.

The gap is not a discrepancy so much as a scope difference, and it closes almost exactly. Bulk drugs and intermediates — APIs — are not classified under Chapter 30 at all; many sit in Chapter 29, organic chemicals, under headings such as antibiotics, heterocyclic compounds and hormones. Adding those headings (HS 2933, 2934, 2937 and 2941) to the Chapter 30 total gives $31.6 billion — within half a percentage point of Pharmexcil’s $31.1 billion.

That reconciliation is itself informative. “Pharma exports” as an industry figure already includes the bulk-drug and API trade that the domestic-dependency story treats as a separate, worrying category. India both exports a meaningful volume of active ingredients under the pharma banner and imports 43 per cent of its API needs from China under a different one. The two are not the same molecules moving in opposite directions, but they sit closer together in the trade classification than the two halves of this story usually acknowledge.

What to watch

• The 2027 Commerce Department review. Whether the US generics exemption survives is the single largest determinant of India’s pharma export trajectory, and it is a policy decision, not a market one.
• Whether FY26 pharma import data, once published, moves the 43.45% China share. The figure in circulation is FY2023-24; a year and a half of PLI commissioning sits between that data point and now.
• Booked BIOSECURE contract revenue, as distinct from analyst sizing. The gap between the two is currently the whole story.
• Whether the Bulk Drugs PLI’s substitution figure moves materially as the 38 commissioned projects ramp to full capacity, or whether ₹2,720 crore turns out to be close to the ceiling of what this scheme size can do.

The honest summary

India’s pharmaceutical export story is real: $31 billion, a near-total exemption from a tariff that could have been severe, and a geopolitical shift that is actively looking for suppliers outside China. None of that is invented.

What sits underneath it is a dependency the export headline does not show, because exports and imports are reported as separate branches and rarely read together. A country supplying 43 per cent of your medicine chemistry, for 97 distinct active ingredients at 70 per cent or more, is not a detail. It is the thing that determines whether “China-free” is a marketing claim India can make or one it can only aspire to. On the numbers available today, it is the second one.

Sources and caveats